Recurrent, metastatic Head and Neck Squamous Cell Carcinoma

Also known as: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma / Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck / Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) / Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma / Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck / Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck / Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck / Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma / Metastatic or Recurrent HNSCC

DrugDrug NameDrug Description
DB09035NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DrugDrug NamePhaseStatusCount
DB09037Pembrolizumab1 / 2Recruiting1
DB15155Pepinemab1 / 2Recruiting1
DB12015Alpelisib2Unknown Status1
DB00958Carboplatin2Recruiting1
DB00002Cetuximab2Recruiting1
DB00515Cisplatin2Completed1
DB00515Cisplatin2Recruiting1
DB17456Dalpiciclib2Recruiting1
DB01248Docetaxel2Completed2
DB00441Gemcitabine2Recruiting1
DB06186Ipilimumab2Completed1
DB17407MRG-0032Recruiting1
DB06192Nimotuzumab2Not Yet Recruiting1
DB09035Nivolumab2Completed1
DB01229Paclitaxel2Recruiting1
DB01269Panitumumab2Completed2
DB09037Pembrolizumab2Recruiting1
DB15765Sintilimab2Not Yet Recruiting1